November 30, 2022
"In Arkansas, for example, we now have half the urologists that there were 25 years ago, and that's with an increasing population. That's a representation of what's going on across the country," says R. Jonathan Henderson, MD.
November 29, 2022
“It certainly seems that we're moving into medical management of advanced diseases,” says J. Christopher Webster, MD, FACS.
November 22, 2022
“From a patient care standpoint, anything that opens the door and makes the patient feel more secure and open is going to lead to better outcomes for them and allow us to serve their needs best,” says Benjamin Lowentritt, MD, FACS.
November 18, 2022
“New imaging has rapidly changed the advanced prostate cancer landscape, and all of the existing studies that we have are based on older imaging,” says Dr. Henderson.
November 16, 2022
"In a phase 2 clinical trial, we saw that erdafitinib had an objective response rate of around 40% in patients who received prior chemotherapy for their metastatic disease," says Dr. Siefker-Radtke.
November 15, 2022
“From just a regular business sense, we can’t raise prices to offset some of our supply cost problems,” says David Morris, MD.
November 14, 2022
"There's 3000 patient trials that are either done or going to be done within the next year or 2 in the BCG-naïve setting, and all of them have systemic therapy," says Joshua J. Meeks, MD, PhD.
"People are starting to retire, and there isn't that much production of urologists every year; there's about 270 that come out for the whole country," says Richard Harris, MD.
November 13, 2022
"We want to make sure that independent urology continues to thrive by recruiting new people to independent urology. That's what we're going to try and do," said Evan R. Goldfischer, MD.
"Specifically for our transgender and gender-diverse patients, there are still insurance issues and access issues in general," said Diana K. Bowen, MD.
